世界の点眼薬市場予測　2023-2032年

KEY FINDINGS
The global ophthalmic drugs market is predicted to project a CAGR of 6.09% during the forecast period, 2023-2032. The market growth is accredited to the vulnerability of the aging population to eye conditions associated with age, progress in drug delivery technologies, increasing incidence of eye diseases and disorders, and positive reimbursement policies implemented by healthcare systems.

MARKET INSIGHTS
Ophthalmic drugs play a crucial role in addressing a spectrum of eye-related conditions, including but not limited to glaucoma, age-related macular degeneration (AMD), dry eye syndrome, and diabetic retinopathy. Ophthalmic drugs encompass a diverse range of drug classes, including anti-inflammatory drugs, anti-infective drugs, anti-glaucoma drugs, and others. These drugs are tailored to address specific disease indications such as inflammation, infections, elevated intraocular pressure, and retinal disorders.
The global increase in the prevalence of eye diseases and disorders can be attributed to a combination of demographic, lifestyle, and environmental factors. One contributing factor is the widespread usage of digital devices, such as smartphones, computers, and tablets, leading to heightened exposure to the blue light emitted by these screens. Prolonged exposure to this blue light can result in digital eye strain, manifesting as symptoms like dry eyes, eye fatigue, and discomfort. Although not a disease on its own, digital eye strain has the potential to worsen existing eye conditions and adversely affect visual comfort.
However, patent expirations and the entry of generic drugs pose challenges to market growth. Untapped potential in emerging economies offers a growth avenue for market players.

REGIONAL INSIGHTS
The global ophthalmic drugs market growth evaluation includes the geographical analysis of North America, Europe, Asia-Pacific, and Rest of World. Asia-Pacific is the fastest-growing region in the global market, driven by various factors such as the increasing prevalence of eye disorders, rising aging population, and advancements in pharmaceutical research and development.

REPORT SYNOPSIS

COMPETITIVE INSIGHTS
The market for ophthalmic drugs on a global scale is characterized by intense competition, as various pharmaceutical companies vie for a share of the market. Major players dedicate substantial resources to research and development endeavors aimed at introducing novel drugs and therapies, fostering a continuous cycle of innovation. Some of the leading companies in the market include AbbVie Inc, Genentech Inc, Bausch Health Companies Inc, etc.
Our report offerings include:

• Explore key findings of the overall market
• Strategic breakdown of market dynamics (Drivers, Restraints, Opportunities, Challenges)
• Market forecasts for a minimum of 9 years, along with 3 years of historical data for all segments, sub-segments, and regions
• Market Segmentation caters to a thorough assessment of key segments with their market estimations
• Geographical Analysis: Assessments of the mentioned regions and country-level segments with their market share
• Key analytics: Porter’s Five Forces Analysis, Vendor Landscape, Opportunity Matrix, Key Buying Criteria, etc.
• The competitive landscape is the theoretical explanation of the key companies based on factors, market share, etc.
• Company profiling: A detailed company overview, product/services offered, SCOT analysis, and recent strategic developments

Inkwood Researchでは世界の主要地域・国別の市場調査レポートも出版しています。各レポートの詳細についてはChosaReport.comまでお問合せください。

• アジア太平洋地域の点眼薬市場予測　2023-2032年
  ASIA-PACIFIC OPHTHALMIC DRUGS MARKET FORECAST 2023-2032
• 欧州の点眼薬市場予測　2023-2032年
  EUROPE OPHTHALMIC DRUGS MARKET FORECAST 2023-2032
• 北米の点眼薬市場予測　2023-2032年
  NORTH AMERICA OPHTHALMIC DRUGS MARKET FORECAST 2023-2032
• カナダの点眼薬市場予測　2023-2030
  CANADA OPHTHALMIC DRUGS MARKET FORECAST 2023-2030

Table of Contents

1. RESEARCH SCOPE & METHODOLOGY
   1.1. STUDY OBJECTIVES
   1.2. METHODOLOGY
   1.3. ASSUMPTIONS & LIMITATIONS
2. EXECUTIVE SUMMARY
   2.1. MARKET SIZE & ESTIMATES
   2.2. MARKET OVERVIEW
   2.3. SCOPE OF STUDY
   2.4. CRISIS SCENARIO ANALYSIS
   2.4.1. IMPACT OF COVID-19 ON OPHTHALMIC DRUGS MARKET
   2.5. MAJOR MARKET FINDINGS
   2.5.1. EMERGING THERAPIES FOR DRY EYE SYNDROME
   2.5.2. GROWING DEMAND FOR COMBINATION THERAPIES
   2.5.3. INCREASING INVESTMENT IN RESEARCH & DEVELOPMENT
   2.5.4. SHIFT TOWARD OVER-THE-COUNTER (OTC) PRODUCTS
3. MARKET DYNAMICS
   3.1. KEY DRIVERS
   3.1.1. AGING POPULATION’S SUSCEPTIBILITY TO AGE-RELATED EYE CONDITIONS
   3.1.2. ADVANCEMENTS IN DRUG DELIVERY TECHNOLOGIES
   3.1.3. RISING PREVALENCE OF EYE DISEASES AND DISORDERS
   3.1.4. FAVORABLE REIMBURSEMENT POLICIES BY HEALTHCARE SYSTEMS
   3.2. KEY RESTRAINTS
   3.2.1. DELAY IN DRUG APPROVALS
   3.2.2. SIDE EFFECTS RELATED TO OPHTHALMIC DRUGS
4. KEY ANALYTICS
   4.1. KEY MARKET TRENDS
   4.2. TECHNOLOGY SNAPSHOT
   4.2.1. BIOLOGICS
   4.2.2. CELL THERAPY
   4.2.3. GENE THERAPY
   4.2.4. DRUG DELIVERY
   4.2.5. SMALL MOLECULE
   4.2.6. OTHER TECHNOLOGIES
   4.3. PORTER’S FIVE FORCES ANALYSIS
   4.3.1. BUYERS POWER
   4.3.2. SUPPLIERS POWER
   4.3.3. SUBSTITUTION
   4.3.4. NEW ENTRANTS
   4.3.5. INDUSTRY RIVALRY
   4.4. GROWTH PROSPECT MAPPING
   4.4.1. GROWTH PROSPECT MAPPING FOR UNITED STATES
   4.4.2. GROWTH PROSPECT MAPPING FOR ITALY
   4.4.3. GROWTH PROSPECT MAPPING FOR INDIA
   4.4.4. GROWTH PROSPECT MAPPING FOR THE MIDDLE EAST & AFRICA
   4.5. MARKET MATURITY ANALYSIS
   4.6. MARKET CONCENTRATION ANALYSIS
   4.7. KEY BUYING CRITERIA
   4.8. REGULATORY FRAMEWORK
5. MARKET BY INDICATION
   5.1. DRY EYE
   5.2. GLAUCOMA
   5.3. INFECTION/INFLAMMATION/ALLERGIES
   5.4. RETINAL DISORDER
   5.4.1. WET AGE-RELATED MACULAR DEGENERATION
   5.4.2. DRY AGE-RELATED MACULAR DEGENERATION
   5.4.3. DIABETIC RETINOPATHY
   5.4.4. OTHER RETINAL DISORDERS
   5.5. OTHER INDICATIONS
6. MARKET BY TYPE
   6.1. PRESCRIPTION DRUGS
   6.2. OVER-THE-COUNTER DRUGS
7. MARKET BY DOSAGE FORM
   7.1. GELS
   7.2. EYE SOLUTIONS & SUSPENSIONS
   7.3. CAPSULES & TABLETS
   7.4. EYE DROPS
   7.5. OINTMENTS
8. MARKET BY THERAPEUTIC CLASS
   8.1. ANTI-GLAUCOMA
   8.2. ANTI-INFECTION
   8.3. ANTI-INFLAMMATORY
   8.4. ANTI-ALLERGY
   8.5. OTHER THERAPEUTIC CLASSES
9. MARKET BY DISTRIBUTION CHANNEL
   9.1. HOSPITAL PHARMACIES
   9.2. DRUG STORES
   9.3. ONLINE PHARMACIES
   9.4. OTHER DISTRIBUTION CHANNELS
10. GEOGRAPHICAL ANALYSIS
    10.1. NORTH AMERICA
    10.1.1. MARKET SIZE & ESTIMATES
    10.1.2. NORTH AMERICA OPHTHALMIC DRUGS MARKET DRIVERS
    10.1.3. NORTH AMERICA OPHTHALMIC DRUGS MARKET CHALLENGES
    10.1.4. KEY PLAYERS IN NORTH AMERICA OPHTHALMIC DRUGS MARKET
    10.1.5. COUNTRY ANALYSIS
    10.1.5.1. UNITED STATES
    10.1.5.1.1. UNITED STATES OPHTHALMIC DRUGS MARKET SIZE & OPPORTUNITIES
    10.1.5.2. CANADA
    10.1.5.2.1. CANADA OPHTHALMIC DRUGS MARKET SIZE & OPPORTUNITIES
    10.2. EUROPE
    10.2.1. MARKET SIZE & ESTIMATES
    10.2.2. EUROPE OPHTHALMIC DRUGS MARKET DRIVERS
    10.2.3. EUROPE OPHTHALMIC DRUGS MARKET CHALLENGES
    10.2.4. KEY PLAYERS IN EUROPE OPHTHALMIC DRUGS MARKET
    10.2.5. COUNTRY ANALYSIS
    10.2.5.1. UNITED KINGDOM
    10.2.5.1.1. UNITED KINGDOM OPHTHALMIC DRUGS MARKET SIZE & OPPORTUNITIES
    10.2.5.2. GERMANY
    10.2.5.2.1. GERMANY OPHTHALMIC DRUGS MARKET SIZE & OPPORTUNITIES
    10.2.5.3. FRANCE
    10.2.5.3.1. FRANCE OPHTHALMIC DRUGS MARKET SIZE & OPPORTUNITIES
    10.2.5.4. ITALY
    10.2.5.4.1. ITALY OPHTHALMIC DRUGS MARKET SIZE & OPPORTUNITIES
    10.2.5.5. SPAIN
    10.2.5.5.1. SPAIN OPHTHALMIC DRUGS MARKET SIZE & OPPORTUNITIES
    10.2.5.6. BELGIUM
    10.2.5.6.1. BELGIUM OPHTHALMIC DRUGS MARKET SIZE & OPPORTUNITIES
    10.2.5.7. POLAND
    10.2.5.7.1. POLAND OPHTHALMIC DRUGS MARKET SIZE & OPPORTUNITIES
    10.2.5.8. REST OF EUROPE
    10.2.5.8.1. REST OF EUROPE OPHTHALMIC DRUGS MARKET SIZE & OPPORTUNITIES
    10.3. ASIA-PACIFIC
    10.3.1. MARKET SIZE & ESTIMATES
    10.3.2. ASIA-PACIFIC OPHTHALMIC DRUGS MARKET DRIVERS
    10.3.3. ASIA-PACIFIC OPHTHALMIC DRUGS MARKET CHALLENGES
    10.3.4. KEY PLAYERS IN ASIA-PACIFIC OPHTHALMIC DRUGS MARKET
    10.3.5. COUNTRY ANALYSIS
    10.3.5.1. CHINA
    10.3.5.1.1. CHINA OPHTHALMIC DRUGS MARKET SIZE & OPPORTUNITIES
    10.3.5.2. JAPAN
    10.3.5.2.1. JAPAN OPHTHALMIC DRUGS MARKET SIZE & OPPORTUNITIES
    10.3.5.3. INDIA
    10.3.5.3.1. INDIA OPHTHALMIC DRUGS MARKET SIZE & OPPORTUNITIES
    10.3.5.4. SOUTH KOREA
    10.3.5.4.1. SOUTH KOREA OPHTHALMIC DRUGS MARKET SIZE & OPPORTUNITIES
    10.3.5.5. INDONESIA
    10.3.5.5.1. INDONESIA OPHTHALMIC DRUGS MARKET SIZE & OPPORTUNITIES
    10.3.5.6. THAILAND
    10.3.5.6.1. THAILAND OPHTHALMIC DRUGS MARKET SIZE & OPPORTUNITIES
    10.3.5.7. VIETNAM
    10.3.5.7.1. VIETNAM OPHTHALMIC DRUGS MARKET SIZE & OPPORTUNITIES
    10.3.5.8. AUSTRALIA & NEW ZEALAND
    10.3.5.8.1. AUSTRALIA & NEW ZEALAND OPHTHALMIC DRUGS MARKET SIZE & OPPORTUNITIES
    10.3.5.9. REST OF ASIA-PACIFIC
    10.3.5.9.1. REST OF ASIA-PACIFIC OPHTHALMIC DRUGS MARKET SIZE & OPPORTUNITIES
    10.4. REST OF WORLD
    10.4.1. MARKET SIZE & ESTIMATES
    10.4.2. REST OF WORLD OPHTHALMIC DRUGS MARKET DRIVERS
    10.4.3. REST OF WORLD OPHTHALMIC DRUGS MARKET CHALLENGES
    10.4.4. KEY PLAYERS IN REST OF WORLD OPHTHALMIC DRUGS MARKET
    10.4.5. REGIONAL ANALYSIS
    10.4.5.1. LATIN AMERICA
    10.4.5.1.1. LATIN AMERICA OPHTHALMIC DRUGS MARKET SIZE & OPPORTUNITIES
    10.4.5.2. MIDDLE EAST & AFRICA
    10.4.5.2.1. MIDDLE EAST & AFRICA OPHTHALMIC DRUGS MARKET SIZE & OPPORTUNITIES
11. COMPETITIVE LANDSCAPE
    11.1. KEY STRATEGIC DEVELOPMENTS
    11.1.1. MERGERS & ACQUISITIONS
    11.1.2. PRODUCT LAUNCHES & DEVELOPMENTS
    11.1.3. PARTNERSHIPS & AGREEMENTS
    11.2. COMPANY PROFILES
    11.2.1. ABBVIE INC
    11.2.1.1. COMPANY OVERVIEW
    11.2.1.2. PRODUCTS & SERVICES
    11.2.1.3. STRENGTHS & CHALLENGES
    11.2.2. ACCUTOME INC
    11.2.2.1. COMPANY OVERVIEW
    11.2.2.2. PRODUCTS & SERVICES
    11.2.2.3. STRENGTHS & CHALLENGES
    11.2.3. BAUSCH HEALTH COMPANIES INC
    11.2.3.1. COMPANY OVERVIEW
    11.2.3.2. PRODUCTS & SERVICES
    11.2.3.3. STRENGTHS & CHALLENGES
    11.2.4. GENENTECH INC
    11.2.4.1. COMPANY OVERVIEW
    11.2.4.2. PRODUCTS & SERVICES
    11.2.4.3. STRENGTHS & CHALLENGES
    11.2.5. JOHNSON & JOHNSON
    11.2.5.1. COMPANY OVERVIEW
    11.2.5.2. PRODUCTS & SERVICES
    11.2.5.3. STRENGTHS & CHALLENGES
    11.2.6. THEA PHARMA INC
    11.2.6.1. COMPANY OVERVIEW
    11.2.6.2. PRODUCTS & SERVICES
    11.2.6.3. STRENGTHS & CHALLENGES
    11.2.7. NOVARTIS AG
    11.2.7.1. COMPANY OVERVIEW
    11.2.7.2. PRODUCTS & SERVICES
    11.2.7.3. STRENGTHS & CHALLENGES
    11.2.8. PFIZER INC
    11.2.8.1. COMPANY OVERVIEW
    11.2.8.2. PRODUCTS & SERVICES
    11.2.8.3. STRENGTHS & CHALLENGES
    11.2.9. REGENERON PHARMACEUTICALS INC
    11.2.9.1. COMPANY OVERVIEW
    11.2.9.2. PRODUCTS & SERVICES
    11.2.9.3. STRENGTHS & CHALLENGES
    11.2.10. SANTEN PHARMACEUTICAL CO LTD
    11.2.10.1. COMPANY OVERVIEW
    11.2.10.2. PRODUCTS & SERVICES
    11.2.10.3. STRENGTHS & CHALLENGES
    11.2.11. SUN PHARMACEUTICAL INDUSTRIES LTD
    11.2.11.1. COMPANY OVERVIEW
    11.2.11.2. PRODUCTS & SERVICES
    11.2.11.3. STRENGTHS & CHALLENGES
    11.2.12. TEVA PHARMACEUTICALS INDUSTRIES LTD
    11.2.12.1. COMPANY OVERVIEW
    11.2.12.2. PRODUCTS & SERVICES
    11.2.12.3. STRENGTHS & CHALLENGES

LIST OF TABLES
TABLE 1: MARKET SNAPSHOT – OPHTHALMIC DRUGS
TABLE 2: REGULATORY FRAMEWORK
TABLE 3: GLOBAL OPHTHALMIC DRUGS MARKET, BY INDICATION, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)
TABLE 4: GLOBAL OPHTHALMIC DRUGS MARKET, BY INDICATION, FORECAST YEARS, 2023-2032 (IN $ MILLION)
TABLE 5: GLOBAL DRY EYE MARKET, BY REGION, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)
TABLE 6: GLOBAL DRY EYE MARKET, BY REGION, FORECAST YEARS, 2023-2032 (IN $ MILLION)
TABLE 7: GLOBAL GLAUCOMA MARKET, BY REGION, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)
TABLE 8: GLOBAL GLAUCOMA MARKET, BY REGION, FORECAST YEARS, 2023-2032 (IN $ MILLION)
TABLE 9: GLOBAL INFECTION/INFLAMMATION/ALLERGIES MARKET, BY REGION, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)
TABLE 10: GLOBAL INFECTION/INFLAMMATION/ALLERGIES MARKET, BY REGION, FORECAST YEARS, 2023-2032 (IN $ MILLION)
TABLE 11: GLOBAL RETINAL DISORDER MARKET, BY REGION, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)
TABLE 12: GLOBAL RETINAL DISORDER MARKET, BY REGION, FORECAST YEARS, 2023-2032 (IN $ MILLION)
TABLE 13: GLOBAL OPHTHALMIC DRUGS MARKET, BY RETINAL DISORDER, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)
TABLE 14: GLOBAL OPHTHALMIC DRUGS MARKET, BY RETINAL DISORDER, FORECAST YEARS, 2023-2032 (IN $ MILLION)
TABLE 15: GLOBAL WET AGE-RELATED MACULAR DEGENERATION MARKET, BY REGION, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)
TABLE 16: GLOBAL WET AGE-RELATED MACULAR DEGENERATION MARKET, BY REGION, FORECAST YEARS, 2023-2032 (IN $ MILLION)
TABLE 17: GLOBAL DRY AGE-RELATED MACULAR DEGENERATION MARKET, BY REGION, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)
TABLE 18: GLOBAL DRY AGE-RELATED MACULAR DEGENERATION MARKET, BY REGION, FORECAST YEARS, 2023-2032 (IN $ MILLION)
TABLE 19: GLOBAL DIABETIC RETINOPATHY MARKET, BY REGION, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)
TABLE 20: GLOBAL DIABETIC RETINOPATHY MARKET, BY REGION, FORECAST YEARS, 2023-2032 (IN $ MILLION)
TABLE 21: GLOBAL OTHER RETINAL DISORDERS MARKET, BY REGION, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)
TABLE 22: GLOBAL OTHER RETINAL DISORDERS MARKET, BY REGION, FORECAST YEARS, 2023-2032 (IN $ MILLION)
TABLE 23: GLOBAL OTHER INDICATIONS MARKET, BY REGION, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)
TABLE 24: GLOBAL OTHER INDICATIONS MARKET, BY REGION, FORECAST YEARS, 2023-2032 (IN $ MILLION)
TABLE 25: GLOBAL OPHTHALMIC DRUGS MARKET, BY TYPE, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)
TABLE 26: GLOBAL OPHTHALMIC DRUGS MARKET, BY TYPE, FORECAST YEARS, 2023-2032 (IN $ MILLION)
TABLE 27: GLOBAL PRESCRIPTION DRUGS MARKET, BY REGION, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)
TABLE 28: GLOBAL PRESCRIPTION DRUGS MARKET, BY REGION, FORECAST YEARS, 2023-2032 (IN $ MILLION)
TABLE 29: GLOBAL OVER-THE-COUNTER DRUGS MARKET, BY REGION, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)
TABLE 30: GLOBAL OVER-THE-COUNTER DRUGS MARKET, BY REGION, FORECAST YEARS, 2023-2032 (IN $ MILLION)
TABLE 31: GLOBAL OPHTHALMIC DRUGS MARKET, BY DOSAGE FORM, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)
TABLE 32: GLOBAL OPHTHALMIC DRUGS MARKET, BY DOSAGE FORM, FORECAST YEARS, 2023-2032 (IN $ MILLION)
TABLE 33: GLOBAL GELS MARKET, BY REGION, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)
TABLE 34: GLOBAL GELS MARKET, BY REGION, FORECAST YEARS, 2023-2032 (IN $ MILLION)
TABLE 35: GLOBAL EYE SOLUTIONS & SUSPENSIONS MARKET, BY REGION, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)
TABLE 36: GLOBAL EYE SOLUTIONS & SUSPENSIONS MARKET, BY REGION, FORECAST YEARS, 2023-2032 (IN $ MILLION)
TABLE 37: GLOBAL CAPSULES & TABLETS MARKET, BY REGION, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)
TABLE 38: GLOBAL CAPSULES & TABLETS MARKET, BY REGION, FORECAST YEARS, 2023-2032 (IN $ MILLION)
TABLE 39: GLOBAL EYE DROPS MARKET, BY REGION, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)
TABLE 40: GLOBAL EYE DROPS MARKET, BY REGION, FORECAST YEARS, 2023-2032 (IN $ MILLION)
TABLE 41: GLOBAL OINTMENTS MARKET, BY REGION, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)
TABLE 42: GLOBAL OINTMENTS MARKET, BY REGION, FORECAST YEARS, 2023-2032 (IN $ MILLION)
TABLE 43: GLOBAL OPHTHALMIC DRUGS MARKET, BY THERAPEUTIC CLASS, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)
TABLE 44: GLOBAL OPHTHALMIC DRUGS MARKET, BY THERAPEUTIC CLASS, FORECAST YEARS, 2023-2032 (IN $ MILLION)
TABLE 45: GLOBAL ANTI-GLAUCOMA MARKET, BY REGION, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)
TABLE 46: GLOBAL ANTI-GLAUCOMA MARKET, BY REGION, FORECAST YEARS, 2023-2032 (IN $ MILLION)
TABLE 47: GLOBAL ANTI-INFECTION MARKET, BY REGION, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)
TABLE 48: GLOBAL ANTI-INFECTION MARKET, BY REGION, FORECAST YEARS, 2023-2032 (IN $ MILLION)
TABLE 49: GLOBAL ANTI-INFLAMMATORY MARKET, BY REGION, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)
TABLE 50: GLOBAL ANTI-INFLAMMATORY MARKET, BY REGION, FORECAST YEARS, 2023-2032 (IN $ MILLION)
TABLE 51: GLOBAL ANTI-ALLERGY MARKET, BY REGION, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)
TABLE 52: GLOBAL ANTI-ALLERGY MARKET, BY REGION, FORECAST YEARS, 2023-2032 (IN $ MILLION)
TABLE 53: GLOBAL OTHER THERAPEUTIC CLASSES MARKET, BY REGION, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)
TABLE 54: GLOBAL OTHER THERAPEUTIC CLASSES MARKET, BY REGION, FORECAST YEARS, 2023-2032 (IN $ MILLION)
TABLE 55: GLOBAL OPHTHALMIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)
TABLE 56: GLOBAL OPHTHALMIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, FORECAST YEARS, 2023-2032 (IN $ MILLION)
TABLE 57: GLOBAL HOSPITAL PHARMACIES MARKET, BY REGION, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)
TABLE 58: GLOBAL HOSPITAL PHARMACIES MARKET, BY REGION, FORECAST YEARS, 2023-2032 (IN $ MILLION)
TABLE 59: GLOBAL DRUG STORES MARKET, BY REGION, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)
TABLE 60: GLOBAL DRUG STORES MARKET, BY REGION, FORECAST YEARS, 2023-2032 (IN $ MILLION)
TABLE 61: GLOBAL ONLINE PHARMACIES MARKET, BY REGION, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)
TABLE 62: GLOBAL ONLINE PHARMACIES MARKET, BY REGION, FORECAST YEARS, 2023-2032 (IN $ MILLION)
TABLE 63: GLOBAL OTHER DISTRIBUTION CHANNELS MARKET, BY REGION, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)
TABLE 64: GLOBAL OTHER DISTRIBUTION CHANNELS MARKET, BY REGION, FORECAST YEARS, 2023-2032 (IN $ MILLION)
TABLE 65: GLOBAL OPHTHALMIC DRUGS MARKET, BY GEOGRAPHY, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)
TABLE 66: GLOBAL OPHTHALMIC DRUGS MARKET, BY GEOGRAPHY, FORECAST YEARS, 2023-2032 (IN $ MILLION)
TABLE 67: NORTH AMERICA OPHTHALMIC DRUGS MARKET, BY COUNTRY, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)
TABLE 68: NORTH AMERICA OPHTHALMIC DRUGS MARKET, BY COUNTRY, FORECAST YEARS, 2023-2032 (IN $ MILLION)
TABLE 69: KEY PLAYERS OPERATING IN NORTH AMERICA OPHTHALMIC DRUGS MARKET
TABLE 70: EUROPE OPHTHALMIC DRUGS MARKET, BY COUNTRY, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)
TABLE 71: EUROPE OPHTHALMIC DRUGS MARKET, BY COUNTRY, FORECAST YEARS, 2023-2032 (IN $ MILLION)
TABLE 72: KEY PLAYERS OPERATING IN EUROPE OPHTHALMIC DRUGS MARKET
TABLE 73: ASIA-PACIFIC OPHTHALMIC DRUGS MARKET, BY COUNTRY, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)
TABLE 74: ASIA-PACIFIC OPHTHALMIC DRUGS MARKET, BY COUNTRY, FORECAST YEARS, 2023-2032 (IN $ MILLION)
TABLE 75: KEY PLAYERS OPERATING IN ASIA-PACIFIC OPHTHALMIC DRUGS MARKET
TABLE 76: REST OF WORLD OPHTHALMIC DRUGS MARKET, BY REGION, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)
TABLE 77: REST OF WORLD OPHTHALMIC DRUGS MARKET, BY REGION, FORECAST YEARS, 2023-2032 (IN $ MILLION)
TABLE 78: KEY PLAYERS OPERATING IN REST OF WORLD OPHTHALMIC DRUGS MARKET
TABLE 79: LIST OF MERGERS & ACQUISITIONS
TABLE 80: LIST OF PRODUCT LAUNCHES & DEVELOPMENTS
TABLE 81: LIST OF PARTNERSHIPS & AGREEMENTS

LIST OF FIGURES
FIGURE 1: KEY MARKET TRENDS
FIGURE 2: PORTER’S FIVE FORCES ANALYSIS
FIGURE 3: GROWTH PROSPECT MAPPING FOR UNITED STATES
FIGURE 4: GROWTH PROSPECT MAPPING FOR ITALY
FIGURE 5: GROWTH PROSPECT MAPPING FOR INDIA
FIGURE 6: GROWTH PROSPECT MAPPING FOR THE MIDDLE EAST & AFRICA
FIGURE 7: MARKET MATURITY ANALYSIS
FIGURE 8: MARKET CONCENTRATION ANALYSIS
FIGURE 9: GLOBAL OPHTHALMIC DRUGS MARKET, GROWTH POTENTIAL, BY INDICATION, IN 2022
FIGURE 10: GLOBAL OPHTHALMIC DRUGS MARKET, BY DRY EYE, 2023-2032 (IN $ MILLION)
FIGURE 11: GLOBAL OPHTHALMIC DRUGS MARKET, BY GLAUCOMA, 2023-2032 (IN $ MILLION)
FIGURE 12: GLOBAL OPHTHALMIC DRUGS MARKET, BY INFECTION/INFLAMMATION/ALLERGIES, 2023-2032 (IN $ MILLION)
FIGURE 13: GLOBAL OPHTHALMIC DRUGS MARKET, BY RETINAL DISORDER, 2023-2032 (IN $ MILLION)
FIGURE 14: GLOBAL OPHTHALMIC DRUGS MARKET, GROWTH POTENTIAL, BY RETINAL DISORDER, IN 2022
FIGURE 15: GLOBAL OPHTHALMIC DRUGS MARKET, BY WET AGE-RELATED MACULAR DEGENERATION, 2023-2032 (IN $ MILLION)
FIGURE 16: GLOBAL OPHTHALMIC DRUGS MARKET, BY DRY AGE-RELATED MACULAR DEGENERATION, 2023-2032 (IN $ MILLION)
FIGURE 17: GLOBAL OPHTHALMIC DRUGS MARKET, BY DIABETIC RETINOPATHY, 2023-2032 (IN $ MILLION)
FIGURE 18: GLOBAL OPHTHALMIC DRUGS MARKET, BY OTHER RETINAL DISORDERS, 2023-2032 (IN $ MILLION)
FIGURE 19: GLOBAL OPHTHALMIC DRUGS MARKET, BY OTHER INDICATIONS, 2023-2032 (IN $ MILLION)
FIGURE 20: GLOBAL OPHTHALMIC DRUGS MARKET, GROWTH POTENTIAL, BY TYPE, IN 2022
FIGURE 21: GLOBAL OPHTHALMIC DRUGS MARKET, BY PRESCRIPTION DRUGS, 2023-2032 (IN $ MILLION)
FIGURE 22: GLOBAL OPHTHALMIC DRUGS MARKET, BY OVER-THE-COUNTER DRUGS, 2023-2032 (IN $ MILLION)
FIGURE 23: GLOBAL OPHTHALMIC DRUGS MARKET, GROWTH POTENTIAL, BY DOSAGE FORM, IN 2022
FIGURE 24: GLOBAL OPHTHALMIC DRUGS MARKET, BY GELS, 2023-2032 (IN $ MILLION)
FIGURE 25: GLOBAL OPHTHALMIC DRUGS MARKET, BY EYE SOLUTIONS & SUSPENSIONS, 2023-2032 (IN $ MILLION)
FIGURE 26: GLOBAL OPHTHALMIC DRUGS MARKET, BY CAPSULES & TABLETS, 2023-2032 (IN $ MILLION)
FIGURE 27: GLOBAL OPHTHALMIC DRUGS MARKET, BY EYE DROPS, 2023-2032 (IN $ MILLION)
FIGURE 28: GLOBAL OPHTHALMIC DRUGS MARKET, BY OINTMENTS, 2023-2032 (IN $ MILLION)
FIGURE 29: GLOBAL OPHTHALMIC DRUGS MARKET, GROWTH POTENTIAL, BY THERAPEUTIC CLASS, IN 2022
FIGURE 30: GLOBAL OPHTHALMIC DRUGS MARKET, BY ANTI-GLAUCOMA, 2023-2032 (IN $ MILLION)
FIGURE 31: GLOBAL OPHTHALMIC DRUGS MARKET, BY ANTI-INFECTION, 2023-2032 (IN $ MILLION)
FIGURE 32: GLOBAL OPHTHALMIC DRUGS MARKET, BY ANTI-INFLAMMATORY, 2023-2032 (IN $ MILLION)
FIGURE 33: GLOBAL OPHTHALMIC DRUGS MARKET, BY ANTI-ALLERGY, 2023-2032 (IN $ MILLION)
FIGURE 34: GLOBAL OPHTHALMIC DRUGS MARKET, BY OTHER THERAPEUTIC CLASSES, 2023-2032 (IN $ MILLION)
FIGURE 35: GLOBAL OPHTHALMIC DRUGS MARKET, GROWTH POTENTIAL, BY DISTRIBUTION CHANNEL, IN 2022
FIGURE 36: GLOBAL OPHTHALMIC DRUGS MARKET, BY HOSPITAL PHARMACIES, 2023-2032 (IN $ MILLION)
FIGURE 37: GLOBAL OPHTHALMIC DRUGS MARKET, BY DRUG STORES, 2023-2032 (IN $ MILLION)
FIGURE 38: GLOBAL OPHTHALMIC DRUGS MARKET, BY ONLINE PHARMACIES, 2023-2032 (IN $ MILLION)
FIGURE 39: GLOBAL OPHTHALMIC DRUGS MARKET, BY OTHER DISTRIBUTION CHANNELS, 2023-2032 (IN $ MILLION)
FIGURE 40: NORTH AMERICA OPHTHALMIC DRUGS MARKET, COUNTRY OUTLOOK, 2022 & 2032 (IN %)
FIGURE 41: UNITED STATES OPHTHALMIC DRUGS MARKET, 2023-2032 (IN $ MILLION)
FIGURE 42: CANADA OPHTHALMIC DRUGS MARKET, 2023-2032 (IN $ MILLION)
FIGURE 43: EUROPE OPHTHALMIC DRUGS MARKET, COUNTRY OUTLOOK, 2022 & 2032 (IN %)
FIGURE 44: UNITED KINGDOM OPHTHALMIC DRUGS MARKET, 2023-2032 (IN $ MILLION)
FIGURE 45: GERMANY OPHTHALMIC DRUGS MARKET, 2023-2032 (IN $ MILLION)
FIGURE 46: FRANCE OPHTHALMIC DRUGS MARKET, 2023-2032 (IN $ MILLION)
FIGURE 47: ITALY OPHTHALMIC DRUGS MARKET, 2023-2032 (IN $ MILLION)
FIGURE 48: SPAIN OPHTHALMIC DRUGS MARKET, 2023-2032 (IN $ MILLION)
FIGURE 49: BELGIUM OPHTHALMIC DRUGS MARKET, 2023-2032 (IN $ MILLION)
FIGURE 50: POLAND OPHTHALMIC DRUGS MARKET, 2023-2032 (IN $ MILLION)
FIGURE 51: REST OF EUROPE OPHTHALMIC DRUGS MARKET, 2023-2032 (IN $ MILLION)
FIGURE 52: ASIA-PACIFIC OPHTHALMIC DRUGS MARKET, COUNTRY OUTLOOK, 2022 & 2032 (IN %)
FIGURE 53: CHINA OPHTHALMIC DRUGS MARKET, 2023-2032 (IN $ MILLION)
FIGURE 54: JAPAN OPHTHALMIC DRUGS MARKET, 2023-2032 (IN $ MILLION)
FIGURE 55: INDIA OPHTHALMIC DRUGS MARKET, 2023-2032 (IN $ MILLION)
FIGURE 56: SOUTH KOREA OPHTHALMIC DRUGS MARKET, 2023-2032 (IN $ MILLION)
FIGURE 57: INDONESIA OPHTHALMIC DRUGS MARKET, 2023-2032 (IN $ MILLION)
FIGURE 58: THAILAND OPHTHALMIC DRUGS MARKET, 2023-2032 (IN $ MILLION)
FIGURE 59: VIETNAM OPHTHALMIC DRUGS MARKET, 2023-2032 (IN $ MILLION)
FIGURE 60: AUSTRALIA & NEW ZEALAND OPHTHALMIC DRUGS MARKET, 2023-2032 (IN $ MILLION)
FIGURE 61: REST OF ASIA-PACIFIC OPHTHALMIC DRUGS MARKET, 2023-2032 (IN $ MILLION)
FIGURE 62: REST OF WORLD OPHTHALMIC DRUGS MARKET, REGIONAL OUTLOOK, 2022 & 2032 (IN %)
FIGURE 63: LATIN AMERICA OPHTHALMIC DRUGS MARKET, 2023-2032 (IN $ MILLION)
FIGURE 64: MIDDLE EAST & AFRICA OPHTHALMIC DRUGS MARKET, 2023-2032 (IN $ MILLION)